Having trouble accessing articles? Reset your cache.

Cenderitide: Completed Phase II enrollment

Capricor completed enrollment of 14 patients in an open-label, dose-escalation,

Read the full 104 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE